Search
Col-118
go.drugbank.com/drugs/DB05778InvestigationalCol-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist. … It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.
LGD-1550
go.drugbank.com/drugs/DB05785ExperimentalLGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalA novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track
GEM-231
go.drugbank.com/drugs/DB05798InvestigationalA monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. … GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase.
NOX-100
go.drugbank.com/drugs/DB05799InvestigationalNOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.
Cositecan
go.drugbank.com/drugs/DB05806InvestigationalCositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
HGTV-43
go.drugbank.com/drugs/DB05807ExperimentalHGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.
NBI-6024
go.drugbank.com/drugs/DB05819InvestigationalNBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
Prolease-r-hFSH
go.drugbank.com/drugs/DB05826ExperimentalIt provides patients with long term therapeutic benefit from a single administration rather than multiple injections. … Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology.
G207
go.drugbank.com/drugs/DB05827InvestigationalMediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.